US cancels mRNA vaccine contracts worth $500 million – DW – 08/06/2025
The US government has decided to halt the funding of 22 projects focused on the development and manufacturing of mRNA-based vaccines that help fight respiratory diseases like COVID-19 and the flu.
The decision, announced by Health Secretary Robert F. Kennedy Jr., stemmed from doubts over vaccines' efficacy and marks the latest attempt in a string of efforts that weave vaccine distrust into US health policy.
"We reviewed the science, listened to the experts, and acted," Kennedy said in a statement.
The health department's Biomedical Advanced Research and Development Authority (BARDA) is "terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu," he added.
In total, the halted projects are worth "nearly $500 million," the Department of Health and Human Services (HHS) said.
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
In a video that he posted on social media, Kennedy criticized mRNA vaccines, explaining the decision to cancel projects being led by the nation's leading pharmaceutical companies, including Pfizer and Moderna, that offer protection against viruses like the flu, COVID-19 and H5N1.
"To replace the troubled mRNA programs, we're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate," Kennedy said in the video.
"Let me be absolutely clear: HHS supports safe, effective vaccines for every American who wants them," he stressed.
The mRNA technology is currently being used for more than infectious disease vaccines, with researchers around the world exploring its use for cancer immunotherapies.
In a statement Tuesday, HHS said "other uses of mRNA technology within the department are not impacted by this announcement."
To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video
Kennedy has been a longtime vaccine critic. Since his appointment as health secretary, he has overseen the remodeling of US health policy.
Kennedy has pulled back recommendations around the COVID-19 shots, fired the panel that makes vaccine recommendations,
and refused to offer a vigorous endorsement of vaccinations as a measles outbreak worsened.
He has also ordered a sweeping new study on the long-debunked link between vaccines and autism.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
DW
21 hours ago
- DW
Experts alarmed by US cuts to mRNA vaccine research – DW – 08/08/2025
US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will boost global vulnerability to future pandemics. The first signs of an overhaul came quickly from the newly inaugurated US President Donald Trump. After being back in power just two months, his administration had already slashed funding for more than 30 research projects related to reasons for and measures against vaccine skepticism. This made it clear to scientists that future mRNA research in the US could also be in jeopardy. At that time, the administration of the National Institutes of Health (NIH), which is responsible for biomedical research, had also requested a list of all NIH-funded research projects dealing with mRNA technology. These were to be forwarded to the Department of Health and Human Services and the White House. A similar request was also made regarding research projects related to vaccine skepticism — before their funding was cut. This week, the Department of Health and Human Services — headed by Health Secretary Robert F. Kennedy Jr., who is known for his opposition to vaccines — announced it would cut $500 million in research funding for mRNA vaccines at the NIH. A statement from the Department of Health and Human Services (HHS) said it would terminate several contracts, reject applications for research funding that had already been submitted and restructure some existing partnerships. "We reviewed the science, listened to the experts, and acted," said Kennedy. Investment in 22 projects dealing with mRNA vaccines will be halted "because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." But experts immediately took issue with his statement. They point out that mRNA vaccines have been used successfully in the COVID pandemic. "Overall mRNA vaccines were responsible for saving millions of lives in the COVID-19 pandemic," said Charles Bangham, professor emeritus of immunology at Imperial College London. "Few, if any, antiviral vaccines will completely prevent the virus from entering the body," Bangham continued. "What the vaccine does is to lessen the severity of the infection, reducing disease and the risk of death." Jaime M. Yassif of the Nuclear Threat Initiative (NTI), a nonprofit organization that campaigns against biological, nuclear and chemical weapons, called the announced funding cuts "a grave mistake." "Halting research on much needed technology for rapidly developing new vaccines makes Americans and the world vulnerable to future pandemics," said Yassif, vice president for biological policy and programs at NTI, in a statement. This applies to both naturally occurring diseases and those that could be developed in a laboratory and used as weapons, she added. Kennedy's claim that mRNA vaccines do not offer reliable protection "is patently false," Yassif said. "If not for the rapid deployment of mRNA vaccines during COVID-19, the cost in lives lost and economic damage would have been far more severe." The German company BioNTech, which developed one of the mRNA coronavirus vaccines in collaboration with the US pharmaceutical company Pfizer, is not affected by the cuts. "We have not received any funds from the US government and have nothing outstanding," a BioNTech spokeswoman told DW. In contrast, cooperation partner Pfizer is mentioned in the HHS' statement under the heading "rejection or cancellation" of proposals. Pfizer shares temporarily lost 3% of their value after Kennedy's decision was announced. The company did not respond to a request for comment from DW. The renowned Emory University in the US state of Georgia is also among those whose contracts with the US government are being wound up. A spokesperson for the university's Woodruff Health Sciences Center told DW that the cutbacks affect a research project involving a drug for the treatment of respiratory diseases such as influenza and COVID-19. The collaboration had only been announced in September 2024. Emory University researchers were planning to test whether the antiviral treatment could be produced as a dry powder that would not require continuous cooling. The funds for this project have now been cut. To view this video please enable JavaScript, and consider upgrading to a web browser that supports HTML5 video The mRNA technology is not only used in vaccines against respiratory diseases. From acne to Lyme disease and dengue fever to AIDS, researchers are looking for mRNA vaccines against a wide variety of diseases. Research is being conducted all over the world, with China and South Korea among the countries working on many projects. The technology also plays an important role in cancer research. In the fight against colon cancer, for example, US researchers are working on a drug that is intended to prevent the cancer from returning after the original tumor has been surgically removed. According to the HHS, funding for such research should be maintained. However, experts are calling for continued support for mRNA vaccine research as well. Cuts in research would limit the US' ability to develop vaccines quickly in the event of a new pandemic, unless "alternative sources of funding can be secured," said Penelope Ward, visiting professor of pharmaceutical medicine at King's College London. Furthermore, she added, the cuts are not just a problem for the US. "It is detrimental to us all."
DW
a day ago
- DW
Experts alarmed by US cuts to mRNA vaccine research
US Health Secretary Robert F Kennedy Jr has slashed US government spending on mRNA vaccine research. Experts warn it will boost our vulnerability to future pandemics. The first signs of an overhaul came quickly from the newly inaugurated US president Donald Trump. After being in power just two months, his administration had already slashed funding for more than 30 research projects relating to vaccine skepticism. This made it clear to scientists that future mRNA research in the US could also be in jeopardy. At that time, the administration of the National Institutes of Health (NIH) had also requested a list of all NIH-funded research projects dealing with mRNA technology. These were to be forwarded to the Department of Health and Human Services and the White House. A similar request had also been made regarding research projects on vaccine skepticism — before their funding was cut. This week, the US Department of Health and Human Services announced that it would cut $500 million in research funding for mRNA vaccines. The NIH is an agency of the US Department of Health and Human Services responsible for biomedical research. It is headed by US Health Secretary Robert F. Kennedy Jr., who is known for his opposition to vaccines. How effective are mRNA vaccines? A statement from the Department of Health and Human Services said it would terminate several contracts, reject applications for research funding that had already been submitted, and restructure some existing partnerships. "We reviewed the science, listened to the experts, and acted," said Health Secretary Kennedy. Investment in 22 projects dealing with mRNA vaccines will be halted "because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu." US Health Secretary Kennedy is a well-known opponent of vaccination and supports the disproved theory that vaccinations can cause autism Image: Morry Gash/AP Photo/File/picture alliance But experts immediately took issue with his statement. They point out that mRNA vaccines have been used successfully in the coronavirus pandemic. "Overall mRNA vaccines were responsible for saving millions of lives in the COVID-19 pandemic," said Charles Bangham, professor emeritus of immunology at Imperial College London. "Few, if any, anti-viral vaccines will completely prevent the virus from entering the body," Bangham continued. "What the vaccine does is to lessen the severity of the infection, reducing disease and the risk of death." Slowing mRNA research leaves us 'more vulnerable to future pandemics' Jaime M. Yassif of the Nuclear Threat Initiative (NTI), a non-profit organization that campaigns against biological, nuclear, and chemical weapons, called the announced funding cuts "a grave mistake." 'Halting research on much needed technology for rapidly developing new vaccines makes Americans and the world vulnerable to future pandemics,' said Yassif, vice president for biological policy and programs at NTI, in a statement. This applies to both naturally occurring diseases and those that could be developed in a laboratory and used as weapons, he added. Health Secretary Kennedy's claim that mRNA vaccines do not offer reliable protection "is patently false," Yassif said. "If not for the rapid deployment of mRNA vaccines during COVID-19, the cost in lives lost and economic damage would have been far more severe." Pharmaceutical company Pfizer shares down on cuts The German company BioNTech, which developed one of the mRNA coronavirus vaccines in collaboration with the US pharmaceutical company Pfizer, is not affected by the cuts. "We have not received any funds from the US government and have nothing outstanding," a BioNTech spokeswoman told DW. In contrast, cooperation partner Pfizer is mentioned in the Health Ministry's statement under the heading "rejection or cancellation" of proposals. Pfizer shares temporarily lost 3% of their value after Kennedy's decision was announced. The company did not respond to a request for comment from DW. The renowned Emory University in the US state of Georgia is also among those whose contracts with the US government are being wound up. A spokesperson for the university's Woodruff Health Sciences Center told DW that the cutbacks affect a research project involving a drug for the treatment of respiratory diseases such as influenza and COVID-19. The collaboration had only been announced in September 2024. Emory University researchers were planning to test whether the antiviral treatment could be produced as a dry powder that would not require continuous cooling. The funds for this project have now been cut. What's in store for mRNA technology after COVID? Research cuts impact beyond the US The mRNA technology is not only used in vaccines against respiratory diseases. From acne to Lyme disease and dengue fever to AIDS, researchers are looking for mRNA vaccines against a wide variety of diseases. Research is being conducted all over the world, with China and South Korea among the countries working on many projects. The technology also plays an important role in cancer research. In the fight against colon cancer, for example, US researchers are working on a drug that is intended to prevent the cancer from returning after the original tumor has been surgically removed. According to the US Department of Health and Human Services, funding for such research should be maintained. However, experts are calling for continued support for mRNA vaccine research as well. Cuts in research would limit the US's ability to develop vaccines quickly in the event of a new pandemic, unless "alternative sources of funding can be secured," says Penelope Ward, visiting professor of pharmaceutical medicine at King's College London. Furthermore, she added, the cuts are not just a problem for the US. "It is detrimental to us all." This article originally appeared in German.
Int'l Business Times
2 days ago
- Int'l Business Times
The Silent Struggle: Raising Awareness About POTS with Dr. Nicholas Tullo
Postural tachycardia syndrome (POTS) is a condition many have never heard of, yet it affects a significant and growing segment of the population. It's a syndrome that can leave once-active individuals bedridden, grappling with a cascade of symptoms that defy easy categorization. Dr. Nicholas Tullo, a seasoned cardiac electrophysiologist and founder of ECG AcademyⓇ, helps patients find answers in this medical terrain. Dr. Tullo has spent decades on the frontlines of cardiac care, specializing in arrhythmias and fainting disorders. He has built a career that spans patient care, academic instruction, and clinical research. Moreover, he founded a dedicated center for the evaluation of fainting and autonomic dysfunction, helping numerous patients who fall into the diagnostic shadows of conventional medicine. As a fellow of a leading professional society for heart rhythm disorders and a certified cardiac device specialist, Dr. Tullo possesses a depth of knowledge in his work. He has led pioneering research projects, implanted next-generation cardiac monitors, and received multiple teaching and clinical recognitions. Notably, he's one of the few specialists in northern New Jersey who treats POTS patients, many of whom travel long distances to see him after exhausting every other option. POTS affects approximately one to three million Americans, impacting one in every 100 teens. A vast majority of POTS patients are female between the ages of 12 and 50. Despite the condition's prevalence, it typically takes years for patients to receive a diagnosis. Many will see several doctors before someone finally connects the dots. "The syndrome can be so misunderstood that patients are frequently told their symptoms are psychological in origin, or worse, imagined," says Dr. Tullo. Fatigue, brain fog, shortness of breath, heart palpitations, trouble sleeping, chest pain, and anxiety are common symptoms. However, because they present in varied combinations and fluctuate throughout the day, they often evade clear diagnosis. Another characteristic of POTS is that symptoms consistently improve when lying down. This positional sensitivity gives the syndrome its name, yet it's still overlooked in clinical settings. "I've seen patients use wearable devices to track their heart rates. They come to appointments with video evidence of lying down and having a normal heart rate. Then, when they stand up, it surges," Dr. Tullo shares. The cardiac electrophysiologist believes that since the onset of the COVID-19 pandemic, the numbers have only increased. A large-scale study attests to this, finding a five-fold increase in POTS incidence post-COVID. Research shows that POTS may have an autoimmune component. In this sense, it functions less like a singular disease and more like a syndrome. Dr. Tullo describes POTS as a condition where the brain, which should regulate the body's response to standing, instead triggers an overwhelming cardiovascular reaction. He explains, "The brain is the leader, the heart is the team player. In POTS, that team effort breaks down." POTS is challenging to treat because there's no one-size-fits-all solution. Dr. Tullo states that standard treatments that work for other heart rate disorders can worsen symptoms. "For example, forcing the heart to slow down, without addressing the root cause, can impair blood flow to the brain. It will just intensify the symptoms the patient is trying to escape," he says. This is why a nuanced and analytical approach is essential. Dr. Tullo doesn't simply treat numbers on a monitor. He investigates each patient's physiological profile to craft a personalized care plan. For some, the issue may stem from blood pooling in the lower extremities. Others may struggle with low blood volume, immune dysregulation, or comorbid autoimmune disorders such as lupus, Sjögren's syndrome, or mast cell activation disorders. Each presentation requires its own strategy. Dr. Tullo also prioritizes education, ensuring patients understand what's happening in their bodies and why. He encourages them to record consultations so they can revisit the information later. Determining the condition is usually the turning point. "I've witnessed many patients reclaim their lives through increased fluid intake, higher salt consumption, compression garments, targeted exercise regimens, and careful medication adjustments. But none of this is possible without first identifying the condition," he states. That's where the healthcare system needs to improve. POTS deserves more attention. "Many medical curricula don't cover autonomic disorders in depth, so general practitioners and even some specialists don't easily recognize the signs. This lack of awareness means many patients suffer for years without adequate support," Dr. Tullo remarks. He is a vocal advocate for change. Dr. Tullo calls for more research funding, particularly in the autoimmune mechanisms suspected to underlie the condition. Promising avenues include immune-modulating drugs and targeted therapies. However, without investment, the field remains a patchwork of trial and error. Amid such uncertainty, the role of a specialist becomes all the more vital. Dr. Tullo offers guidance for many who have felt invisible within the space. He's helping shift the landscape by elevating awareness, pushing for better education, and advocating for systemic research.
